Which people with metastatic prostate cancer benefit most from upfront docetaxel?
Which people with metastatic prostate cancer benefit most from upfront docetaxel?
New results from our first STOPCAP M1 individual participant data meta-analysis have been published in The Lancet Oncology and show that adding docetaxel to hormone therapy is more beneficial for some people with advanced prostate cancer than others.
2022 STOPCAP M1 Collaborators meeting
Once again, we held a STOPCAP M1 Colloborators Meeting to coincide with ESMO. This year...Paris...
STOPCAP M1 Results ASCO 2022
The latest STOPCAP M1 results were presented at American Society of Clinical Oncology (ASCO) Meeting in Chicago, by Dr Claire Vale and Dr Susan Halabi Claire Vale presented results of a meta-analysis of patient data from 2261 men with metastatic hormone sensitive prostate cancer (mHSPC) in 3 trials showed that on average, chemotherapy improved 5-year survival by 11% compare ...
Second Movember-ICECaP Webinar
The STOPCAP Team are participating in the second Movember-ICECaP webinar on Wednesday 4th May 2022
October 2021 Update
Click below to read about our STOPCAP M1 activities over the last few months and also what is coming next. October Newsletter ...